Biopolitics and Biocapital in Global Health Systems
Summary
The intersection of biopolitics and biocapital in global health systems examines how states, markets and societies govern life itself and derive economic value from biological processes. Biopolitics refers to the array of regulatory strategies and interventions through which populations are managed, from vaccination programmes to genomic surveillance. Biocapital describes the economic dynamics that transform biological materials, data and practices into marketable assets. Together, these twin logics shape policy decisions, industrial innovation and ethical debates across national and transnational health infrastructures. Recent developments in synthetic biology, data-driven platforms and assetisation of intellectual property have accelerated the commodification of life forms and the recalibration of public health priorities. The shift towards platform-based health services and venture-funded biotechnology ventures underscores a broader neoliberal trajectory, whereby public resources and collective well-being are increasingly enmeshed with private capital and speculative futures. At the same time, emerging governance frameworks seek to reconcile equitable access, regulatory oversight and commercial incentives, highlighting persistent tensions between social justice and profit-driven models of biological innovation. This overview integrates insights into regulatory adaptations, evolving market architectures and the ethical contours of biopolitical power in global health.
Research from Nature Portfolio
Recent studies have illuminated the rapid democratisation of synthetic genome technologies and their repercussions for global health governance. Advances in DNA writing platforms have dramatically reduced costs and timeframes for constructing bespoke genetic sequences, prompting calls for updated regulatory architectures to prevent misuse while fostering responsible innovation. Parallel work on DNA-based tagging has demonstrated how biologically encoded identifiers can enhance the traceability of biological samples, pharmaceuticals and supply-chain components, creating new markets for secure labelling and quality assurance. These developments exemplify how breakthroughs in molecular engineering translate into fresh modes of biocapital accumulation, as well as novel biopolitical challenges in balancing open science, intellectual property rights and public health imperatives.
Biopolitics and Biocapital in Global Health Systems publication trend
The graph below shows the total number of articles in biopolitics and biocapital in global health systems across all publications each year (not limited to Nature Index journals).
Technical terms
Biopolitics: The governance of populations through regulatory, administrative and disciplinary mechanisms that manage health, reproduction and life processes.
Biocapital: The economic value generated from biological entities, processes and data, often through commodification, intellectual property and marketisation.
Assetisation: The transformation of rights or processes (for example, drug patents) into financial assets that can be bought, sold and leveraged within capital markets.
Platformisation: The organisation of services and data exchange through digital platforms, reshaping traditional institutional roles and creating new modes of surveillance and monetisation.
Synthetic genomics: The design and construction of artificial genetic materials, enabling tailor-made biological functions and raising novel regulatory and commercial questions.
References
- DNA writing technologies moving toward synthetic genomes. Nature Biotechnology (2023).
- Unlocking the potential of DNA-based tagging: current market solutions and expanding horizons. Nature Communications (2023).
- Global Fertility Chains: An Integrative Political Economy Approach to Understanding the Reproductive Bioeconomy. Science Technology & Human Values (2021).
- Platform NHS: Reconfiguring a Public Service in the Age of Digital Capitalism. Science Technology & Human Values (2021).
- (De-)assetizing pharmaceutical patents: Patent contestations behind a blockbuster drug. Economy and Society (2021).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.